| US3321407A (en)* | 1964-07-02 | 1967-05-23 | Rosenfeld Myer | Ethylenediamine-tetrahydrofuran paint-stripping compositions |
| US3322677A (en)* | 1964-07-02 | 1967-05-30 | Rosenfeld Myer | Ethylenediamine-anisole paint-stripping compositions |
| US3324037A (en)* | 1964-07-02 | 1967-06-06 | Rosenfeld Myer | Thixotropic ethylenediamine-based paint strippers |
| US3324039A (en)* | 1964-07-02 | 1967-06-06 | Rosenfeld Myer | Ethylenediamine-n, n-dimethylformamide paint-stripping compositions |
| US3637508A (en)* | 1970-03-06 | 1972-01-25 | William B Willsey | Process and composition for dissolving copper oxide |
| US4152306A (en)* | 1976-02-26 | 1979-05-01 | LDMJ Limited | Windshield cleaning solvent |
| US4213873A (en)* | 1978-03-10 | 1980-07-22 | Leisure Products Corporation | Water based window, glass and chrome cleaner composition |
| US4556509A (en)* | 1984-10-09 | 1985-12-03 | Colgate-Palmolive Company | Light duty detergents containing an organic diamine diacid salt |
| US4693886A (en)* | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
| US5391381A (en)* | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
| US5236689A (en)* | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
| US5340590A (en)* | 1987-06-25 | 1994-08-23 | Alza Corporation | Delivery system with bilayer osmotic engine |
| US4969884A (en)* | 1988-12-28 | 1990-11-13 | Alza Corporation | Osmotically driven syringe |
| US5126142A (en)* | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
| US5273752A (en)* | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
| US5035897A (en)* | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
| US5030216A (en)* | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
| US5474785A (en)* | 1990-01-24 | 1995-12-12 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| US5312389A (en)* | 1990-10-29 | 1994-05-17 | Felix Theeuwes | Osmotically driven syringe with programmable agent delivery |
| US5151093A (en)* | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
| US7736668B2 (en) | 1991-06-27 | 2010-06-15 | Janssen Pharmaceutica Nv | System for delaying drug delivery up to seven hours |
| US5240713A (en)* | 1991-09-27 | 1993-08-31 | Alza Corporation | Dual rate agent delivery device |
| US5200194A (en)* | 1991-12-18 | 1993-04-06 | Alza Corporation | Oral osmotic device |
| US5817615A (en)* | 1992-02-07 | 1998-10-06 | The Clorox Company | Reduced residue hard surface cleaner |
| US5437807A (en)* | 1992-02-07 | 1995-08-01 | The Clorox Company | Reduced residue hard surface cleaner |
| US5468423A (en)* | 1992-02-07 | 1995-11-21 | The Clorox Company | Reduced residue hard surface cleaner |
| US5523024A (en)* | 1992-02-07 | 1996-06-04 | The Clorox Company | Reduced residue hard surface cleaner |
| US5252245A (en)* | 1992-02-07 | 1993-10-12 | The Clorox Company | Reduced residue hard surface cleaner |
| US20040092601A1 (en)* | 1993-05-27 | 2004-05-13 | Edgren David Emil | Antidepressant dosage form |
| US8084059B2 (en) | 1993-05-27 | 2011-12-27 | Alza Corporation | Antidepressant dosage form |
| US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| US20040086570A1 (en)* | 1993-05-27 | 2004-05-06 | Edgren David Emil | Antidepressant dosage form |
| US20070009600A1 (en)* | 1993-05-27 | 2007-01-11 | Edgren David E | Antidepressant dosage form |
| US5707663A (en)* | 1993-05-28 | 1998-01-13 | Alza Corporation | Sustained antiepileptic therapy |
| US5980943A (en)* | 1993-05-28 | 1999-11-09 | Alza Corporation | Sustained antiepileptic therapy |
| US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| US5532003A (en)* | 1994-01-18 | 1996-07-02 | Alza Corporation | Pentoxifylline therapy |
| US5603954A (en)* | 1994-01-18 | 1997-02-18 | Alza Corporation | Pentoxifylline therapy and method of use |
| US5540665A (en)* | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
| US20040191314A1 (en)* | 1994-04-28 | 2004-09-30 | Frank Jao | Antiepileptic dosage form and process for protecting antiepileptic drug |
| US20010038856A1 (en)* | 1994-07-07 | 2001-11-08 | Sonya Merrill | Hydromorphone therapy |
| US20100028389A1 (en)* | 1994-07-07 | 2010-02-04 | Sonya Merrill | Hydromorphone therapy |
| US5851981A (en)* | 1995-03-24 | 1998-12-22 | The Clorox Company | Reduced residue hard surface cleaner |
| US5990065A (en)* | 1996-12-20 | 1999-11-23 | The Procter & Gamble Company | Dishwashing detergent compositions containing organic diamines for improved grease cleaning, sudsing, low temperature stability and dissolution |
| US6069122A (en)* | 1997-06-16 | 2000-05-30 | The Procter & Gamble Company | Dishwashing detergent compositions containing organic diamines for improved grease cleaning, sudsing, low temperature stability and dissolution |
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| US20040062799A1 (en)* | 1997-09-29 | 2004-04-01 | Ayer Atul D. | Therapeutic composition and delivery system for administering drug |
| US6727212B2 (en) | 1997-11-10 | 2004-04-27 | The Procter & Gamble Company | Method for softening soil on hard surfaces |
| US6210712B1 (en) | 1997-12-05 | 2001-04-03 | Alza Corporation | Dosage form having first and second coats |
| US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US20070122348A1 (en)* | 1997-12-22 | 2007-05-31 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US20100291203A1 (en)* | 1997-12-22 | 2010-11-18 | Purdue Pharma L.P. | Opioid Agonist/Antagonist Combinations |
| US20080292694A1 (en)* | 1997-12-22 | 2008-11-27 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US20050192309A1 (en)* | 1997-12-22 | 2005-09-01 | Palermo Philip J. | Method of preventing abuse of opioid dosage forms |
| US9474750B2 (en) | 1997-12-22 | 2016-10-25 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US7172767B2 (en) | 1997-12-22 | 2007-02-06 | Purdue Pharma L.P. | Opioid agonist / antagonist combinations |
| US9205082B2 (en) | 1997-12-22 | 2015-12-08 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US8105631B2 (en) | 1997-12-22 | 2012-01-31 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
| US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US8936808B1 (en) | 1997-12-22 | 2015-01-20 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US20020058673A1 (en)* | 1997-12-22 | 2002-05-16 | Kaiko Robert F. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US7749542B2 (en) | 1997-12-22 | 2010-07-06 | Purdue Pharma Lp | Opioid agonist/antagonist combinations |
| US7419686B2 (en) | 1997-12-22 | 2008-09-02 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US20040086561A1 (en)* | 1997-12-22 | 2004-05-06 | Kaiko Robert F. | Opioid agonist / antagonist combinations |
| US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| US20070128279A1 (en)* | 1998-03-06 | 2007-06-07 | Alza Corporation | Extended Release Dosage Form |
| US8524277B2 (en) | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
| US6589926B1 (en) | 1998-06-02 | 2003-07-08 | Procter & Gamble Company | Dishwashing detergent compositions containing organic diamines |
| US20090130204A1 (en)* | 1998-09-08 | 2009-05-21 | Encinal Pharmaceutical Investment Inc. | Dosage Form Comprising Therapeutic Formulation |
| US20080181944A1 (en)* | 1998-09-08 | 2008-07-31 | Alza Corporation | Dosage Form Comprising Therapeutic Formulation |
| US20030157163A1 (en)* | 1998-09-08 | 2003-08-21 | Liang-Chang Dong | Dosage form comprising therapeutic formulation |
| US6551613B1 (en) | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
| US20100159002A1 (en)* | 1998-09-08 | 2010-06-24 | Liang-Chang Dong | Dosage form comprising therapeutic formulation |
| WO2000023663A1 (en) | 1998-10-21 | 2000-04-27 | Reckitt Benckiser (Uk) Limited | Dispensing device |
| US6510561B1 (en) | 1998-10-21 | 2003-01-28 | Reckitt Benckiser (Uk) Limited | Dispensing device |
| US20020048600A1 (en)* | 1998-11-02 | 2002-04-25 | Padmanabh Bhatt | Controlled delivery of active agents |
| US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
| US6855334B2 (en) | 1998-11-02 | 2005-02-15 | Alta Corporation | Controlled delivery of active agents |
| EP1652516A2 (en) | 1998-11-02 | 2006-05-03 | ALZA Corporation | Osmotic controlled delivery of active agents |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US6596314B2 (en) | 1998-12-23 | 2003-07-22 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| WO2000062764A1 (en) | 1999-04-20 | 2000-10-26 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
| US20020071863A1 (en)* | 1999-12-09 | 2002-06-13 | Dong Liang C. | Antiviral medication |
| EP2932964A1 (en) | 2000-10-30 | 2015-10-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| EP2011485A2 (en) | 2001-05-02 | 2009-01-07 | Euro-Celtique S.A. | Once-a-day oxycodone formulations |
| EP3146963A1 (en) | 2001-05-02 | 2017-03-29 | Euro-Celtique S.A. | Once-a-day oxycodone formulations |
| US9168252B2 (en) | 2001-05-11 | 2015-10-27 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9511066B2 (en) | 2001-05-11 | 2016-12-06 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9056051B2 (en) | 2001-05-11 | 2015-06-16 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9084729B2 (en) | 2001-05-11 | 2015-07-21 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9161937B2 (en) | 2001-05-11 | 2015-10-20 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9283221B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9283216B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9345701B1 (en) | 2001-05-11 | 2016-05-24 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9358230B1 (en) | 2001-05-11 | 2016-06-07 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9480685B2 (en) | 2001-05-11 | 2016-11-01 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US20030069263A1 (en)* | 2001-07-18 | 2003-04-10 | Breder Christopher D. | Pharmaceutical combinations of oxycodone and naloxone |
| US7943173B2 (en) | 2001-07-18 | 2011-05-17 | Purdue Pharma L.P. | Pharmaceutical combinations of oxycodone and naloxone |
| US20060182801A1 (en)* | 2001-08-06 | 2006-08-17 | Christopher Breder | Sequestered antagonist formulations |
| US10206881B2 (en) | 2001-08-06 | 2019-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9877924B2 (en) | 2001-08-06 | 2018-01-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9387174B2 (en) | 2001-08-06 | 2016-07-12 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9861583B2 (en) | 2001-08-06 | 2018-01-09 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9387173B2 (en) | 2001-08-06 | 2016-07-12 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9517207B2 (en) | 2001-08-06 | 2016-12-13 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US20100168148A1 (en)* | 2001-08-06 | 2010-07-01 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US9308170B2 (en) | 2001-08-06 | 2016-04-12 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9867784B2 (en) | 2001-08-06 | 2018-01-16 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9308171B2 (en) | 2001-08-06 | 2016-04-12 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9968559B2 (en) | 2001-08-06 | 2018-05-15 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9867783B2 (en) | 2001-08-06 | 2018-01-16 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US20030157168A1 (en)* | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
| USRE45822E1 (en) | 2001-08-06 | 2015-12-22 | Purdue Pharma L.P. | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US10064825B2 (en) | 2001-08-06 | 2018-09-04 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US10064824B2 (en) | 2001-08-06 | 2018-09-04 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US10071057B2 (en) | 2001-08-06 | 2018-09-11 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US10076497B2 (en) | 2001-08-06 | 2018-09-18 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US10130586B2 (en) | 2001-08-06 | 2018-11-20 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US8337888B2 (en) | 2001-08-06 | 2012-12-25 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9693961B2 (en) | 2001-08-06 | 2017-07-04 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9757341B2 (en) | 2001-08-06 | 2017-09-12 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9060976B2 (en) | 2001-08-06 | 2015-06-23 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9861582B2 (en) | 2001-08-06 | 2018-01-09 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9044435B2 (en) | 2001-08-06 | 2015-06-02 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US7384653B2 (en) | 2001-08-06 | 2008-06-10 | Purdue Pharma L.P. | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US9040084B2 (en) | 2001-08-06 | 2015-05-26 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9034376B2 (en) | 2001-08-06 | 2015-05-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US9872836B2 (en) | 2001-08-06 | 2018-01-23 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US8999961B2 (en) | 2001-08-06 | 2015-04-07 | Purdue Pharma, L.P. | Pharmaceutical formulation containing gelling agent |
| US8389007B2 (en) | 2001-08-06 | 2013-03-05 | Purdue Pharma L.P. | Pharmaceutical composition containing gelling agent |
| US8465774B2 (en) | 2001-08-06 | 2013-06-18 | Purdue Pharma L.P. | Sequestered antagonist formulations |
| US8529948B1 (en) | 2001-08-06 | 2013-09-10 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US20050063909A1 (en)* | 2001-08-06 | 2005-03-24 | Euro-Celtique, S.A. | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US10500160B2 (en) | 2001-08-06 | 2019-12-10 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US8609683B2 (en) | 2001-08-06 | 2013-12-17 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US8871265B2 (en) | 2001-08-06 | 2014-10-28 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US8758825B2 (en) | 2001-08-06 | 2014-06-24 | Purdue Pharma L.P. | Sequestered antagonist formulations |
| US20090081287A1 (en)* | 2001-08-06 | 2009-03-26 | Purdue Pharma L.P. | Pharmaceutical Composition Containing Gelling Agent |
| US11135171B2 (en) | 2001-08-06 | 2021-10-05 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US10537526B2 (en) | 2001-08-06 | 2020-01-21 | Purdue Pharma L.P. | Pharmaceutical formulation containing gelling agent |
| US20030232082A1 (en)* | 2001-09-28 | 2003-12-18 | Shun-Por Li | Modified release dosage forms |
| US20030125714A1 (en)* | 2001-12-18 | 2003-07-03 | Edgren David Emil | Dosage form for time-varying patterns of drug delivery |
| US20070207204A1 (en)* | 2001-12-18 | 2007-09-06 | Alza Corporation | Dosage Form for Time-Varying Patterns of Drug Delivery |
| US20030198619A1 (en)* | 2001-12-19 | 2003-10-23 | Dong Liang C. | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US20030232078A1 (en)* | 2001-12-19 | 2003-12-18 | Dong Liang C. | Formulation & dosage form for the controlled delivery of therapeutic agents |
| US20050245483A1 (en)* | 2002-04-05 | 2005-11-03 | Bianca Brogmann | Matrix for sustained, invariant and independent release of active compounds |
| US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
| US10420762B2 (en) | 2002-04-05 | 2019-09-24 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
| US9655855B2 (en) | 2002-04-05 | 2017-05-23 | Purdue Pharma L.P. | Matrix for sustained, invariant and independent release of active compounds |
| US20050245556A1 (en)* | 2002-04-05 | 2005-11-03 | Bianca Brogmann | Pharmaceutical preparation containing oxycodone and naloxone |
| US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
| US9907793B2 (en) | 2002-04-05 | 2018-03-06 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
| US9555000B2 (en) | 2002-04-05 | 2017-01-31 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
| US20040010000A1 (en)* | 2002-04-29 | 2004-01-15 | Ayer Atul D. | Methods and dosage forms for controlled delivery of oxycodone |
| US20050106249A1 (en)* | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
| US20040091529A1 (en)* | 2002-06-26 | 2004-05-13 | David Edgren | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| US10525053B2 (en) | 2002-07-05 | 2020-01-07 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
| US20050232995A1 (en)* | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US20040115262A1 (en)* | 2002-07-29 | 2004-06-17 | Frank Jao | Formulations and dosage forms for controlled delivery of topiramate |
| US9393192B2 (en) | 2002-07-29 | 2016-07-19 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US20090202631A1 (en)* | 2002-07-29 | 2009-08-13 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US20060134196A1 (en)* | 2002-12-17 | 2006-06-22 | Abbott Gmbh & Co. Kg | Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| US7259186B2 (en) | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| US20080051411A1 (en)* | 2002-12-17 | 2008-02-28 | Cink Russell D | Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof |
| US20050148594A1 (en)* | 2002-12-17 | 2005-07-07 | Cink Russell D. | Salts of fenofibric acid and pharmaceutical formulations thereof |
| US20040166160A1 (en)* | 2003-01-14 | 2004-08-26 | Ramkumar Subramanian | Methods and dosage forms with modified viscosity layers |
| US20040197407A1 (en)* | 2003-02-11 | 2004-10-07 | Ramkumar Subramanian | Methods and dosage forms with modified layer geometry |
| EP1905435A2 (en) | 2003-03-11 | 2008-04-02 | Euro-Celtique S.A. | Titration dosing regimen for controlled release tramadol |
| US10092519B2 (en) | 2003-04-21 | 2018-10-09 | Purdue Pharma L.P. | Pharmaceutical products |
| US9149436B2 (en) | 2003-04-21 | 2015-10-06 | Purdue Pharma L.P. | Pharmaceutical product comprising a sequestered agent |
| US20070259014A1 (en)* | 2003-06-20 | 2007-11-08 | Vgx Pharmaceuticals, Inc. | Compositions for and Methods for Treating Hiv |
| US20050058707A1 (en)* | 2003-08-06 | 2005-03-17 | Iran Reyes | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
| US20050136108A1 (en)* | 2003-08-22 | 2005-06-23 | Yam Noymi V. | Stepwise delivery of topiramate over prolonged period of time |
| EP2298303A1 (en) | 2003-09-25 | 2011-03-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
| US20050158382A1 (en)* | 2003-09-26 | 2005-07-21 | Evangeline Cruz | Controlled release formulations of opioid and nonopioid analgesics |
| US8226979B2 (en) | 2003-09-26 | 2012-07-24 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
| US20050089570A1 (en)* | 2003-09-26 | 2005-04-28 | Evangeline Cruz | Oros push-stick for controlled delivery of active agents |
| US20050112195A1 (en)* | 2003-09-26 | 2005-05-26 | Evangeline Cruz | Drug coating providing high drug loading and methods for providing same |
| US8246986B2 (en) | 2003-09-26 | 2012-08-21 | Alza Corporation | Drug coating providing high drug loading |
| US20050129765A1 (en)* | 2003-11-14 | 2005-06-16 | Shaoling Li | Controlled release of topiramate in liquid dosage forms |
| US20050169992A1 (en)* | 2003-12-23 | 2005-08-04 | Frank Jao | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| US20050175690A1 (en)* | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms |
| US20050175697A1 (en)* | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms of topiramate |
| US20050175696A1 (en)* | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
| US20080206337A1 (en)* | 2004-03-05 | 2008-08-28 | Hai Yong Huang | Method of making dosage forms comprising polymeric compositions |
| US20050196447A1 (en)* | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| US20050196448A1 (en)* | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
| US20050196446A1 (en)* | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| US9777011B2 (en) | 2004-03-30 | 2017-10-03 | Purdue Pharma L.P. | Process for preparing oxycodone compositions |
| EP2305683A1 (en) | 2004-03-30 | 2011-04-06 | Euro-Celtique S.A. | Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US11384091B2 (en) | 2004-03-30 | 2022-07-12 | Purdue Pharma L.P. | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US11236098B2 (en) | 2004-03-30 | 2022-02-01 | Purdue Pharma L.P. | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US10407434B2 (en) | 2004-03-30 | 2019-09-10 | Purdue Pharma L.P. | Process for preparing oxycodone compositions |
| US7674798B2 (en) | 2004-03-30 | 2010-03-09 | Purdue Pharma L.P. | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US20090227615A1 (en)* | 2004-03-30 | 2009-09-10 | Purdue Pharma Lp | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US7129248B2 (en) | 2004-03-30 | 2006-10-31 | Euro-Celtique, S.A. | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US10259819B2 (en) | 2004-03-30 | 2019-04-16 | Purdue Pharma L.P. | Process for preparing oxycodone compositions |
| US10689389B2 (en) | 2004-03-30 | 2020-06-23 | Purdue Pharma L.P. | Process for preparing oxycodone compositions |
| US10696684B2 (en) | 2004-03-30 | 2020-06-30 | Purdue Pharma L.P. | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
| US20070117830A1 (en)* | 2004-03-30 | 2007-05-24 | Euro-Celtique S.A. | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US20100152449A1 (en)* | 2004-03-30 | 2010-06-17 | Purdue Pharma Lp | 8a,14-DIHYDROXY-7,8-DIHYDROCODEINONE |
| US20050222188A1 (en)* | 2004-03-30 | 2005-10-06 | Euro-Celtique S.A. | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
| EP2319846A1 (en) | 2004-03-30 | 2011-05-11 | Euro-Celtique S.A. | Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone |
| US20070117829A1 (en)* | 2004-03-30 | 2007-05-24 | Euro-Celtique S.A. | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US8822687B2 (en) | 2004-03-30 | 2014-09-02 | Purdue Pharma L.P. | 8a,14-dihydroxy-7,8-dihydrocodeinone |
| EP2316837A1 (en) | 2004-03-30 | 2011-05-04 | Euro-Celtique S.A. | Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone |
| US20070117831A1 (en)* | 2004-03-30 | 2007-05-24 | Euro-Celtique S.A. | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US9522919B2 (en) | 2004-03-30 | 2016-12-20 | Purdue Pharma L.P. | Oxycodone compositions |
| US7674800B2 (en) | 2004-03-30 | 2010-03-09 | Purdue Pharma L.P. | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
| US20070179169A1 (en)* | 2004-03-30 | 2007-08-02 | Euro-Celtique S.A. | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
| US12060361B2 (en) | 2004-03-30 | 2024-08-13 | Purdue Pharma L.P. | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US7674799B2 (en) | 2004-03-30 | 2010-03-09 | Purdue Pharma L.P. | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| US9073933B2 (en) | 2004-03-30 | 2015-07-07 | Purdue Pharma L.P. | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
| EP2426132A1 (en) | 2004-03-30 | 2012-03-07 | Euro-Celtique S.A. | Process for preparing 14-hydroxycodeinone from thebaine |
| EP2311839A1 (en) | 2004-03-30 | 2011-04-20 | Euro-Celtique S.A. | Oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone |
| US7683072B2 (en) | 2004-03-30 | 2010-03-23 | Purdue Pharma L.P. | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| EP2314589A1 (en) | 2004-03-30 | 2011-04-27 | Euro-Celtique S.A. | Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone |
| US20060009425A1 (en)* | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| EP2255808A2 (en) | 2004-06-08 | 2010-12-01 | Euro-Celtique S.A. | Opioids for the treatment of the restlessness of the lower limbs |
| EP1961421A1 (en) | 2004-06-08 | 2008-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
| US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
| US10525052B2 (en) | 2004-06-12 | 2020-01-07 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
| US7713550B2 (en) | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| US20050276850A1 (en)* | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Controlled release sodium valproate formulation |
| US20050276848A1 (en)* | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| US20050287214A1 (en)* | 2004-06-28 | 2005-12-29 | Ayer Atul D | Squeeze controlled oral dosage form |
| US20050287212A1 (en)* | 2004-06-28 | 2005-12-29 | Liang-Chang Dong | Oral delivery system comprising a drug/polymer complex |
| US20050287213A1 (en)* | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
| US20060057206A1 (en)* | 2004-08-19 | 2006-03-16 | Wong Patrick S | Controlled release nanoparticle active agent formulation dosage forms and methods |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| US20070281018A1 (en)* | 2004-09-24 | 2007-12-06 | Abbott Laboratories | Sustained release formulations of opioid and nonopioid analgesics |
| US8071073B2 (en) | 2004-11-24 | 2011-12-06 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| US10064817B2 (en) | 2004-11-24 | 2018-09-04 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| EP2377557A2 (en) | 2004-11-24 | 2011-10-19 | MedPointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| WO2006058022A1 (en) | 2004-11-24 | 2006-06-01 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20070020330A1 (en)* | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US8518919B2 (en) | 2004-11-24 | 2013-08-27 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| EP2486942A1 (en) | 2004-11-24 | 2012-08-15 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| US20060110331A1 (en)* | 2004-11-24 | 2006-05-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20100152147A1 (en)* | 2004-11-24 | 2010-06-17 | Meda Pharmaceuticals Inc. | Compositions Comprising Azelastine and Methods of Use Thereof |
| US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
| EP2522365A1 (en) | 2004-11-24 | 2012-11-14 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| EP2965753A1 (en) | 2004-12-03 | 2016-01-13 | Osmotica Kereskedelmi És Szolgáltató Kft | Osmotic device containing amantadine and an osmotic salt |
| US20060165798A1 (en)* | 2005-01-27 | 2006-07-27 | Edgren David E | Oral osmotic dosage form having a high flux membrane |
| US20070259045A1 (en)* | 2005-01-28 | 2007-11-08 | Euro-Celtique S.A. | Alcohol Resistant Dosage Forms |
| US20060193877A1 (en)* | 2005-02-28 | 2006-08-31 | Pfab, Lp | Compositions and methods of making sustained release liquid formulations |
| US9522120B2 (en) | 2005-02-28 | 2016-12-20 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
| US20110172259A1 (en)* | 2005-02-28 | 2011-07-14 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
| US8318210B2 (en) | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| US20110237675A1 (en)* | 2005-04-08 | 2011-09-29 | Abbott Laboratories | Pharmaceutical formulations |
| EP2074992A1 (en) | 2005-04-08 | 2009-07-01 | Abbott Laboratories | Pharmaceutical formulations |
| US20080152714A1 (en)* | 2005-04-08 | 2008-06-26 | Yi Gao | Pharmaceutical Formulations |
| US20060233882A1 (en)* | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
| US20060257484A1 (en)* | 2005-04-19 | 2006-11-16 | Hwang Stephen S | Combination of tramadol and substances that comprise gabapentin |
| US20090221621A1 (en)* | 2005-10-31 | 2009-09-03 | Alza Corporation | Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms |
| WO2007053698A2 (en) | 2005-10-31 | 2007-05-10 | Alza Corporation | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
| US20100172989A1 (en)* | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| US20090317355A1 (en)* | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| US20090169626A1 (en)* | 2006-01-27 | 2009-07-02 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| US20090011018A1 (en)* | 2006-12-28 | 2009-01-08 | Astellas Pharma Inc., | Sustained release formulation for tacrolimus |
| WO2008084698A1 (en) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Tacrolimus sustained release pharmaceutical composition |
| US20080214629A1 (en)* | 2007-02-09 | 2008-09-04 | Scott Bull | Controlled release compositions of tizanidine |
| US8524749B2 (en) | 2007-02-09 | 2013-09-03 | Alza Corporation | Controlled release compositions of tizanidine |
| US8895061B2 (en) | 2007-03-02 | 2014-11-25 | Meda Pharmaceuticals Inc. | Compositions comprising carisoprodol and methods of use thereof |
| US20100189782A1 (en)* | 2007-03-02 | 2010-07-29 | Gul Balwani | Compositions Comprising Carisoprodol and Methods of Use Thereof |
| US8313770B2 (en) | 2007-05-30 | 2012-11-20 | Neos Therapeutics, Lp | Modifying drug release in suspensions of ionic resin systems |
| US20090011027A1 (en)* | 2007-05-30 | 2009-01-08 | Neos Therapeutics, Lp | Modifying Drug Release in Suspensions of Ionic Resin Systems |
| US20090022798A1 (en)* | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
| US20090087484A1 (en)* | 2007-09-28 | 2009-04-02 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
| US20110177133A1 (en)* | 2008-07-07 | 2011-07-21 | Michael Hopp | Use of opioid antagonists for treating urinary retention |
| EP3045043A1 (en) | 2009-02-26 | 2016-07-20 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
| WO2010099508A1 (en) | 2009-02-26 | 2010-09-02 | Theraquest Biosciences, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
| US9820983B2 (en) | 2009-03-10 | 2017-11-21 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US20100260858A1 (en)* | 2009-04-09 | 2010-10-14 | Elan Pharma International Limited | Drug delivery composition |
| US20100260859A1 (en)* | 2009-04-09 | 2010-10-14 | Elan Pharma International Limited | Controlled-release clozapine compositions |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| WO2011122524A1 (en) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | Controlled release pharmaceutical composition |
| US9750703B2 (en) | 2010-12-22 | 2017-09-05 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US8808740B2 (en) | 2010-12-22 | 2014-08-19 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US11590082B2 (en) | 2010-12-22 | 2023-02-28 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US9572779B2 (en) | 2010-12-22 | 2017-02-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US10966932B2 (en) | 2010-12-22 | 2021-04-06 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US11911512B2 (en) | 2010-12-22 | 2024-02-27 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US9393206B2 (en) | 2010-12-22 | 2016-07-19 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US9861584B2 (en) | 2010-12-22 | 2018-01-09 | Purdue Pharma L.P. | Tamper resistant controlled release dosage forms |
| US20160158158A1 (en) | 2010-12-22 | 2016-06-09 | Purdue Pharma L.P. | Encased Tamper Resistant Controlled Release Dosage Forms |
| US9872837B2 (en) | 2010-12-22 | 2018-01-23 | Purdue Pharma L.P. | Tamper resistant controlled release dosage forms |
| US9744136B2 (en) | 2010-12-22 | 2017-08-29 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| US9895317B2 (en) | 2010-12-23 | 2018-02-20 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
| US9707180B2 (en) | 2010-12-23 | 2017-07-18 | Purdue Pharma L.P. | Methods of preparing tamper resistant solid oral dosage forms |
| WO2014013313A1 (en) | 2012-07-16 | 2014-01-23 | Rhodes Technologies | Process for improved opioid synthesis |
| US11390627B2 (en) | 2012-07-16 | 2022-07-19 | Rhodes Technologies | Process for improved opioid synthesis |
| US10316042B2 (en) | 2012-07-16 | 2019-06-11 | Rhodes Technologies | Process for improved opioid synthesis |
| WO2014013311A1 (en) | 2012-07-16 | 2014-01-23 | Rhodes Technologies | Process for improved opioid synthesis |
| US10202396B2 (en) | 2012-07-16 | 2019-02-12 | Rhodes Technologies | Process for improved opioid synthesis |
| US12280025B2 (en) | 2012-11-02 | 2025-04-22 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11026900B2 (en) | 2012-11-02 | 2021-06-08 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US12364675B2 (en) | 2012-11-02 | 2025-07-22 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US10206891B2 (en) | 2012-11-02 | 2019-02-19 | Murray And Poole Enterprises Ltd | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
| US11026901B2 (en) | 2012-11-02 | 2021-06-08 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11026899B2 (en) | 2012-11-02 | 2021-06-08 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11944595B2 (en) | 2012-11-02 | 2024-04-02 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US10265281B2 (en) | 2012-11-02 | 2019-04-23 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US10842762B2 (en) | 2012-11-02 | 2020-11-24 | Murray And Poole Enterprises Ltd | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
| US10842761B2 (en) | 2012-11-02 | 2020-11-24 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11944594B2 (en) | 2012-11-02 | 2024-04-02 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11666545B2 (en) | 2012-11-02 | 2023-06-06 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US12233035B2 (en) | 2012-11-02 | 2025-02-25 | Murray And Poole Enterprises Ltd | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin |
| US9545448B2 (en) | 2013-02-05 | 2017-01-17 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9655971B2 (en) | 2013-02-05 | 2017-05-23 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9662399B2 (en) | 2013-02-05 | 2017-05-30 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US11576974B2 (en) | 2013-02-05 | 2023-02-14 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US10478504B2 (en) | 2013-02-05 | 2019-11-19 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9579389B2 (en) | 2013-02-05 | 2017-02-28 | Purdue Pharma L.P. | Methods of preparing tamper resistant pharmaceutical formulations |
| US9149533B2 (en) | 2013-02-05 | 2015-10-06 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US10792364B2 (en) | 2013-02-05 | 2020-10-06 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US10517832B2 (en) | 2013-03-15 | 2019-12-31 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9616030B2 (en) | 2013-03-15 | 2017-04-11 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US10195152B2 (en) | 2013-03-15 | 2019-02-05 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US11648206B2 (en) | 2013-04-16 | 2023-05-16 | Murray And Poole Enterprises Ltd | Sustained-release formulations of colchicine and methods of using same |
| US10105319B2 (en) | 2013-04-16 | 2018-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| WO2014170755A2 (en) | 2013-04-16 | 2014-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| US10610488B2 (en) | 2013-04-16 | 2020-04-07 | Murray & Poole Enterprises, Ltd. | Sustained-release formulations of colchicine and methods of using same |
| US10130585B2 (en) | 2013-04-16 | 2018-11-20 | Murray And Poole Enterprises Limited | Methods of treating and/or preventing cardiovascular disease |
| WO2014179453A1 (en) | 2013-04-30 | 2014-11-06 | Abbvie, Inc. | Methods for improving lipid profiles using atrasentan |
| US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| US9938285B2 (en) | 2014-01-15 | 2018-04-10 | Rhodes Technologies | Process for improved oxymorphone synthesis |
| US10844072B2 (en) | 2014-01-15 | 2020-11-24 | Rhodes Technologies | Process for improved oxycodone synthesis |
| US9932348B2 (en) | 2014-01-15 | 2018-04-03 | Rhodes Technologies | Process for improved oxycodone synthesis |
| US10189852B2 (en) | 2014-01-15 | 2019-01-29 | Rhodes Technologies | Process for improved oxymorphone synthesis |
| WO2015107472A1 (en) | 2014-01-15 | 2015-07-23 | Rhodes Technologies | Process for improved oxymorphone synthesis |
| WO2015107471A1 (en) | 2014-01-15 | 2015-07-23 | Rhodes Technologies | Process for improved oxycodone synthesis |
| US10428079B2 (en) | 2014-01-15 | 2019-10-01 | Rhodes Technologies | Process for improved oxycodone synthesis |
| WO2016132233A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics |
| WO2016132220A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release oral dosage form of gaba receptor agonist |
| WO2016132217A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Method of improving gaba-b receptor agonist therapy |
| WO2016132218A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Method of administering r-baclofen in an extended release dosage form |
| WO2016134846A1 (en) | 2015-02-27 | 2016-09-01 | Rottapharm Ltd. | Composition for the treatment of acne |
| WO2016166732A1 (en) | 2015-04-17 | 2016-10-20 | Murray And Poole Enterprises Limited | Colchicine salicylate and uses thereof |
| WO2017008909A1 (en) | 2015-07-16 | 2017-01-19 | Rottapharm S. P. A. | Oral formulation comprising berberine and morus alba extract |
| US10646485B2 (en) | 2016-06-23 | 2020-05-12 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| US12226421B2 (en) | 2016-09-09 | 2025-02-18 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| US11013747B2 (en) | 2016-09-09 | 2021-05-25 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| WO2019149884A1 (en) | 2018-02-02 | 2019-08-08 | Murray & Poole Enterprises, Ltd | Use of colchicine to inhibit tumor growth and metastases |
| WO2021029430A1 (en) | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | Oral pharmaceutical composition containing heterocyclic compound |
| WO2021029429A1 (en) | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | Oral pharmaceutical composition |
| WO2021089715A1 (en) | 2019-11-06 | 2021-05-14 | Murray And Poole Enterprises, Ltd. | Use of colchicine in the treatment and prevention of lung cancer |
| EP4364738A2 (en) | 2020-06-10 | 2024-05-08 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| WO2021252741A1 (en) | 2020-06-10 | 2021-12-16 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| US11311488B2 (en) | 2020-06-10 | 2022-04-26 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| WO2023240186A1 (en) | 2022-06-08 | 2023-12-14 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |